Variations in GLP-1R rs2268641 increase risk of diabetic nephropathy in China

doi:10.16352/j.issn.1001-6325.2025.09.1190

Abstract

Abstract: Objective To investigate the association between glucagon-like peptide-1 receptor (GLP-1R) gene polymorphism (rs2268641) and the incidence of diabetic nephropathy (DN) in patients with type 2 diabetes mellitus (T2DM). Methods A total of 490 T2DM patients with or without DN were included in this project. GLP-1R genetic polymorphisms were genotyped with TaqMan allelic discrimination. Results The C allele of rs2268641 was significantly associated with DN in T2DM patients. As compare to urinary albumin excretion rate(UAER) among genotypes, CC homozygote had a higher level of UAER than CT heterozygous (P＜0.01) and TT homozygote(P＜0.05) respectively. CC homozygote had a higher level of UAER than the carriers of the T allele(P＜0.05). Univariate logistic regression analysis showed that CC homozygote had higher odds for DN than CT heterozygote (OR:1.715, 95% CI=1.058-2.778, P＜0.05), even after adjustment for age, gender, family history, FBG and HbA1c (OR:1.781, 95% CI=1.076-2.947, P＜0.05). Moreover, the CC homozygote had higher odds for DN than the carriers of the T allele before (OR:1.585, 95% CI=1.013-2.481, P＜0.05) and after adjustment (OR:1.660, 95% CI=1.040-2.650, P＜0.05). Conclusions GLP-1R gene variants, especially the C allele of rs2268641 increase the risk of DN in Chinese T2DM patients.

Key words: type 2 diabetes mellitus, diabetic nephropathy, glucagon-like peptide-1 receptor(GLP-1R), genetic polymorphism

CLC Number:

R587.1

HE Ke, YANG Fan, LU Xiwan, HU Yun. Variations in GLP-1R rs2268641 increase risk of diabetic nephropathy in China[J]. Basic & Clinical Medicine, 2025, 45(9): 1190-1194.

References

[1] Wal P, Tyagi S, Pal RS, et al. A strategic investigation on diabetic nephropathy; Its conceptual model and clinical manifestations: a review[J]. Curr Diabetes Rev, 2023, 19: e260422204036. doi:10.2174/1573399818666220426091238.
[2] 张雅慧,白琼.低氧诱导因子-1α在糖尿病肾病中作用机制的研究进展[J].基础医学与临床,2024,44:114-118.
[3] Song J, Ni J, Yin X. The genetic side of diabetic kidney disease: a review[J]. Int Urol Nephrol, 2023, 55: 335-343.
[4] Bailey CJ, Flatt PR, Conlon JM. An update on peptide-based therapies for type 2 diabetes and obesity[J]. Peptides, 2023, 161:170939. doi:10.1016/j.peptides.2023.170939.
[5] Gao W, Liu L, Huh E, et al. Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity[J]. Nat Metab, 2023, 5: 1673-1684.
[6] Drucker DJ, Holst JJ. The expanding incretin universe: from basic biology to clinical translation[J]. Diabetologia, 2023,66:1765-1779.
[7] Panda SP. Role of DPP4 and DPP4i in glucose homeo-stasis and cardiorenal syndrome[J]. Endocr Metab Immune Disord Drug Targets, 2023, 23:179-187.
[8] Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential[J]. Kidney international, 2014,85:579-589. doi:10.1038/ki.2013.427.
[9] Ojima A, Ishibashi Y, Matsui T, et al. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression[J]. Am J Pathol, 2013,182:132-141.
[10] Zhao X, Liu G, Shen H, et al. Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells[J]. Int J Mol Med, 2015, 35: 684-692.
[11] Hattori S. Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus[J]. Diabetol Metab Syndr, 2021, 13:117. doi:10.1186/s13098-021-00735-3.
[12] Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J]. New England J Med, 2013, 369:1317-1326.
[13] Zhang L, Zhang W, Tian X. The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases[J]. Int J Neurosci, 2023,133:473-491.
[14] Michałowska J, Miller-Kasprzak E, Seraszek-Jaros A, et al. Association of GLP1R variants rs2268641 and rs6923761 with obesity and other metabolic parameters in a Polish cohort[J]. Front Endocrinol (Lausanne), 2022, 13:1000185. doi:10.3389/fendo.2022.1000185.
[15] Koole C, Wootten D, Simms J, et al. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation[J]. Mole Pharmacol, 2011, 80:486-497.